EPLAW PATENT BLOG

CJEU – Phoenix v. Harting

Posted: April 29th, 2022

Preliminary ruling under Article 267 TFEU in the case between Phoenix Contact GmbH & Co. KG v. HARTING Deutschland GmbH & Co. KG, Harting Electric GmbH & Co. KG, 28 April 2022, Case No. C‑44/21, ECLI:EU:C:2022:309 “By its question, the referring court asks, in essence, whether Article 9(1) of Directive 2004/48 must be interpreted as […]

READ MORE

News – 2022 LES International Annual Conference

Posted: March 29th, 2022

The 2022 LES International Annual Conference will take place in Venezia (Italy) from 8 to 10 May 2022 EPLAW members are welcome to attend the conference, entitled: “Back to Licensing: Restarting Business and Fueling Innovation” The conference website provides information on the program & registrations: www.lesi2022.org. More information can also be found here (The letter […]

READ MORE

EU – Public Consultation on new framework for standard-essential patents

Posted: February 22nd, 2022

The Commission opened a public consultation an a new framework for standard-essential patents As the Commission states in the summary: “A patent that protects technology essential to a standard is called a standard-essential patent (SEP). Patent-holders commit to licence their SEPs to users of the standard on fair, reasonable and non-discriminatory terms and conditions. However, […]

READ MORE

NO – Norwegian Parliament establishes patent attorney client-attorney privilege

Posted: December 2nd, 2021

Norwegian Parliament adopts amendment act establishing patent attorney client-attorney privilege, by Gunnar Meyer and Nora Bratheim, Wikborg Rein The Norwegian Parliament has passed amendments to the Dispute Act and the Criminal Procedure Act extending the general client-privilege rules to patent attorneys. As an outline, patent attorneys now enjoy the same client-attorney privilege as lawyers. However, […]

READ MORE

EPO – G 1/21 – Videoconference

Posted: November 16th, 2021

EBoA of the EPO, decision of July 2021, published on October 28, 2021, case no. G 1/21, reported by Dr. Georg Anetsberger and Dr.-Ing. Felix Grödl, BARDEHLE PAGENBERG In the case G 1/21, the question was referred to the Enlarged Board of Appeal (EBoA) of the EPO, whether conducting oral proceedings in the form of […]

READ MORE

SE – Update Swedish Patent and Market Courts

Posted: November 8th, 2021

The Swedish Patent and Market Courts continue to show progress regarding patent litigations, by Erik Ficks, Roschier Introduction As of 1 September 2021, five years had passed since Sweden unveiled its latest specialist IP courts, namely the Patent and Market Court and the Patent and Market Court of Appeal. Roschier has previously analysed the courts’ […]

READ MORE

DE – German parliament adopts government bill for a Second Act concerning the Simplification and Modernization of German Patent Law

Posted: July 20th, 2021

On June 10, 2021, the German parliament adopted the version of the government bill for a Second Act concerning the Simplification and Modernization of German Patent Law (parliamentary paper 19/25821) as amended by the Committee of Legal Affairs and Consumer Protection (parliamentary paper 19/30498; “Patent Law Modernization Act” below). The Patent Law Modernization Act expressly […]

READ MORE

News – Book Launch: “The Protection of Intellectual Property Rights under International Investment Law”

Posted: May 20th, 2021

On May 27, 2021 a virtual webinar will be celebrating the launch of “The Protection of Intellectual Property Rights under International Investment Law” by Simon Klopschinski, Christopher S. Gibson, Henning Grosse Ruse-Khan “This comprehensive monograph provides detailed analysis and treatment for the complex interplay between the protection of intellectual property rights and international investment law, […]

READ MORE

EU – Antitrust: Commission opens formal investigation into possible anticompetitive conduct of Teva in relation to Copaxone

Posted: March 5th, 2021

From the press release: “The European Commission has opened a formal antitrust investigation to assess whether the pharmaceutical company Teva has illegally delayed the market entry and uptake of medicines that compete with its blockbuster multiple sclerosis drug Copaxone. The Commission will investigate whether Teva has abused a dominant market position in breach of EU […]

READ MORE